ReviewDer Internist2019
[Influenza].
Review in Der Internist, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.
- Coronavirus Disease 2019 (COVID-19) CT Findings: A Systematic Review and Meta-analysis.Journal of the American College of Radiology : JACR · 2020Pooled it
- Beneficial effect of sequential treatment with high-dose steroids and short-course oral glucocorticoids in patients with severe influenza virus-associated pneumonia.Scientific reports · 2024Article
- Immune checkpoint inhibitor-induced neurotoxicity is not associated with seroprevalence of neurotropic infections.Cancer immunology, immunotherapy : CII · 2023Article
- Subacute thyroiditis presenting as simple acute headache was misdiagnosed as meningitis: case report and literature review.BMC endocrine disorders · 2023Review
- The Effect of Drugs with α-Glutamyl-Tryptophan for Cytokine Secretion and Level of Surface Molecule ICAM-1 In Vitro.Cell and tissue biology · 2023Article
- Chest multidetector computed tomography imaging of COVID-19 pneumonia patients with hematologic malignancies.Blood research · 2022Article
- Taming of Covid-19: potential and emerging application of mesenchymal stem cells.Cytotechnology · 2021Review
- Clinical manifestation and disease progression in COVID-19 infection.Journal of the Chinese Medical Association : JCMA · 2021Review
- The recent challenges of highly contagious COVID-19, causing respiratory infections: Symptoms, diagnosis, transmission, possible vaccines, animal models, and immunotherapy.Chemical biology & drug design · 2020Review
- Overview of coronavirus disease 2019: Treatment updates and advances.Journal of the Chinese Medical Association : JCMA · 2020Review
- Coronavirus Disease 2019 (COVID-19): A Perspective from China.Radiology · 2020Review
- A Review of SARS-CoV-2 and the Ongoing Clinical Trials.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe influenza virus (IV)-associated mortality and morbidity remains high in Europe.
objectiveThis article gives an overview of the pathogenesis, diagnostics and treatment optimization strategies according to the currently existing guidelines and clinical trials. MATERIAL AND
methodsLiterature search and analysis of national and international guidelines for the epidemiology, diagnostics, treatment and prevention of IV infections. RESULTS AND
conclusionAlthough the incidence of IV infections remains underrecognized, it is the leading infectious disease-associated cause of mortality and morbidity in Europe. Viruses are mainly transmitted by aerosol inhalation and can cause a wide spectrum of symptoms, ranging from mild signs of a cold to severe respiratory failure requiring mechanical ventilation. The clinical diagnosis should be verified through a PCR-based test in patients with indications for treatment. Neuraminidase inhibitors are currently the treatment of choice for IV infections. Seasonal influenza vaccination is an efficient preventive method. It is therefore imperative to improve vaccination rates in Germany, which have been continuously declining since the pandemic of 2009/2010.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.